Norris Michael H, Khan Mohammad S R, Chirakul Sunisa, Schweizer Herbert P, Tuanyok Apichai
Department of Infectious Diseases and Immunology, College of Veterinary Medicine; University of Florida, Gainesville, FL 32608, USA.
Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA.
Vaccines (Basel). 2018 Jan 10;6(1):5. doi: 10.3390/vaccines6010005.
is a host-adapted Gram-negative mammalian pathogen that causes the severe disease glanders. Glanders can manifest as a rapid acute progression or a chronic debilitating syndrome primarily affecting solipeds and humans in close association with infected animals. In USA, is classified as one of the most important bacterial biothreat agents. Presently, there is no licensed glanders vaccine available for humans or animals. In this work, outer membrane vesicles (OMVs) were isolated from three attenuated biosafe bacterial strains, Bp82, E555, and TxDOH and used to vaccinate mice. OMVs induced significantly higher antibody responses that were investigated. specific serum antibody responses were of higher magnitude in mice vaccinated with OMVs compared to levels in mice vaccinated with OMVs. OMVs derived from biosafe strains protected mice from acute lethal glanders with vesicles from the two strains affording significant protection (>90%) up to 35 days post-infection with some up to 60 days. Organ loads from 35-day survivors indicated bacteria colonization of the lungs, liver, and spleen while those from 60 days had high CFUs in the spleens. The highest antibody producing vaccine ( E555 OMVs) also protected C57BL/6 mice from acute inhalational glanders with evidence of full protection.
是一种宿主适应性革兰氏阴性哺乳动物病原体,可导致严重的鼻疽病。鼻疽病可表现为快速急性进展或慢性衰弱综合征,主要影响单蹄动物以及与受感染动物密切接触的人类。在美国,它被列为最重要的细菌性生物威胁因子之一。目前,尚无用于人类或动物的许可鼻疽病疫苗。在这项工作中,从三种减毒生物安全细菌菌株(Bp82、E555和TxDOH)中分离出外膜囊泡(OMV),并用于给小鼠接种疫苗。对OMV诱导的显著更高的抗体反应进行了研究。与接种TxDOH OMV的小鼠相比,接种E555 OMV的小鼠中特异性血清抗体反应的强度更高。来自生物安全菌株的OMV保护小鼠免受急性致死性鼻疽病的侵害,来自两种Bp82菌株的囊泡在感染后35天内提供了显著保护(>90%),有些甚至长达60天。35天存活小鼠的器官负荷表明肺部、肝脏和脾脏有细菌定植,而60天存活小鼠的脾脏中有高菌落形成单位。产生抗体最高的疫苗(E555 OMV)也保护C57BL/6小鼠免受急性吸入性鼻疽病的侵害,有完全保护的证据。